Full TitleJet-Injection Assisted Photodynamic Therapy for Basal Cell Carcinoma
The purpose of this study is to assess the use of jet-injection-assisted photodynamic therapy (PDT) to treat people with basal cell carcinoma, a common form of skin cancer. PDT uses a drug that increases the sensitivity of skin cells to light and a particular type (wavelength) of light to kill cancer cells. When the drug is exposed to the light, it is activated to destroy cancer cells. The U.S. Food and Drug Administration has approved PDT for actinic keratosis, a type of skin condition caused by years of sun exposure.
Researchers are doing this study to find out whether injecting the drug into the skin with a jet-injection device and activating it with light is a safe treatment for people with basal cell carcinoma. They also want to see how well this therapy works to treat this disease. Most patients will receive two PDT treatments; some patients will receive one PDT treatment followed by skin cancer surgery.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have previously untreated low-risk basal cell carcinoma.
- Patients must have a smartphone and be able to take photos of their lesion and submit them along with ratings of their pain level using a secure study app.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Anthony Rossi at 646-888-6022.